Guiling Li

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

Xiangyu Gao, Nong Xu, Ziyu Li et al. · The Lancet Oncology · 2023 · 171 citations

Oncology, Medicine, Advanced Solid Tumours +8

Ovarian Masses in Children and Adolescents - An Analysis of 521 Clinical Cases

Mingxing Zhang, Wei Jiang, Guiling Li et al. · Journal of Pediatric and Adolescent Gynecology · 2013 · 130 citations

Infertility, Gynecological Surgery, Ovarian Masses +13

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

Xiaohua Wu, Yang Sun, Hongying Yang et al. · The Lancet · 2024 · 73 citations

Metastatic Cervical Cancer, Cervical Cancer, Placebo-controlled Phase 3 +9

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

Xiaohua Wu, Jiafu Ji, Hanmei Lou et al. · Gynecologic Oncology · 2022 · 60 citations

Cervical Cancer, Phase Ii Trial, Medicine +8

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer

Yumeng Wang, Congwen Wang, Junjun Qiu et al. · Journal for ImmunoTherapy of Cancer · 2022 · 59 citations · Full text